Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00388388|
Recruitment Status : Terminated (Few subjects recruited, sponsor withdrew support.)
First Posted : October 16, 2006
Last Update Posted : May 19, 2015
Sir Mortimer B. Davis - Jewish General Hospital
Merck Frosst Canada Ltd.
Information provided by (Responsible Party):
Ernesto L. Schiffrin, Sir Mortimer B. Davis - Jewish General Hospital
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Terminated|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||December 2009|
Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000 Apr 11;101(14):1653-9.
Park JB, Intengan HD, Schiffrin EL. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension. J Renin Angiotensin Aldosterone Syst. 2000 Mar;1(1):40-5. Erratum in: J Renin Angiotensin Aldosterone Syst 2000 Jun;1(2):124.
Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens. 2002 Jan;20(1):71-8.